Fosdenopterin Medication Guide: Standard Medication Guidance

Fosdenopterin (trade name Nulibry®) is a cyclic pyranopterin monophosphate (cPMP) drug used to treat A molybdenum cofactor deficiency (MoCD-A). The taking method and dosage must strictly follow the doctor's instructions to ensure the efficacy and reduce adverse reactions.

Fosdenopterin is a freeze-dried powder for injection. It needs to be administered by intravenous infusion and cannot be taken orally or intramuscularly. Use an infusion pump to control the infusion rate. The recommended infusion rate is 1.5 mL/min.

Reconstitute the lyophilized powder with sterile water for injection, gently rotate the bottle until completely dissolved, and avoid vigorous shaking. The reconstituted solution needs to be kept at room temperature (15°C to 25°C) or refrigerated (2 °C to 8°C) conditions, up to 4 hours (including infusion time). After reconstitution, the solution cannot be heated or refrozen.

Light protection is required during the infusion process. You can use a light-proof infusion set or cover it with light-proof material. Assess the patient's vital signs before infusion to ensure there are no contraindications to infusion (such as allergic history, infection, etc.).

The dose of fosdenopterin is adjusted according to the patient's age and weight, as follows:

Premature infants (<37 weeks gestational age):

Initial dose:0.4 mg/kg/day

After the 1 month: 0.7 mg/kg/day

After the 3 months: 0.9 mg/kg/day

Term infants (≥37 weeks gestational age):

Initial dose:0.55 mg/kg/day

After the 1 month: 0.75 mg/kg/day

After the 3 months: 0.9 mg/kg/day

Children 1years old and above:

Dose:0.9 mg/kg/day

A single infusion volume shall not exceed 1 bottle (9.5 mg). Adjust the dosage under the guidance of a physician based on patient tolerance and efficacy.

Patients need to avoid direct sunlight and ultraviolet exposure, and use protective clothing, hats and sunscreen when going out. The patient's vital signs need to be monitored during the infusion process. If allergic reactions such as fever, chills, rash, etc. occur, the infusion should be stopped immediately and treated accordingly. There are no known interactions between fosdenopterin and other medications, but doctors should be informed of all medications the patient is taking.

There is currently no relevant data for pregnant and lactating women, and use should be done under the guidance of a doctor after weighing the pros and cons. Patients with hepatic and renal insufficiency do not need to adjust the dose, but drug concentrations and adverse reactions need to be closely monitored.

Reference materials:https://nulibry.com/